Hematology Oncology and Stem Cell Therapy Hematology Oncology and Stem Cell Therapy RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Splenic Marginal Zone Lymphoma Associated with Hepatitis B Virus Infection, Remission after Viral Treatment, and Splenectomy: A Case Report and Review of the Literature
We report the case of a patient diagnosed with a splenic marginal zone lymphoma with a simultaneous finding of hepatitis B virus infection, who responded to antiviral treatment and splenectomy. We highlighted this association described in the literature and its possible causal role, as well as the available therapeutic choices. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - July 10, 2019 Category: Cancer & Oncology Source Type: research

Cytokine Release Syndrome and Neurologic Toxicities Associated with Chimeric Antigen Receptor T-Cell Therapy: A Comprehensive Review of Emerging Grading Models
Publication date: Available online 10 June 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Julio C. Chavez, Michael D. Jain, Mohamed A. Kharfan-DabajaAbstractAdvances in the fields of immuno-oncology and T-cell engineering have brought autologous chimeric antigen receptor T-cell (CART) therapies from the bench to the bedside. At present, two CART products that target CD19 are commercially available: tisagenlecleucel and axicabtagene ciloleucel. They have demonstrated remarkable efficacy for their particular indications. One challenge is to compare the safety among commercially available and clinical trial C...
Source: Hematology Oncology and Stem Cell Therapy - June 11, 2019 Category: Cancer & Oncology Source Type: research

Bortezomib for Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
Publication date: Available online 10 June 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Ibrahim N. Muhsen, Ali Alahmari, Mohammed Alnahedh, Nora A. Alkhudair, Hadeel Samarkandi, Riad El Fakih (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - June 11, 2019 Category: Cancer & Oncology Source Type: research

Extramedullary Hematopoiesis Occurring as a Gastric Polyp in a Woman with a Myeloproliferative Disorder
Publication date: Available online 10 June 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Badr AbdullGaffar, Sharifa Karam, Basam Odeh (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - June 11, 2019 Category: Cancer & Oncology Source Type: research

Special Report: Summary of the First Meeting of African Blood and Marrow Transplantation (AfBMT) Group, Casablanca, Morocco, April 19–21, 2018 held under the auspices of the Worldwide Network for Blood and Marrow Transplantation (WBMT)
Publication date: Available online 4 June 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Mhamed HarifAbstractThe first meeting of the African Blood and Marrow Transplantation (AfBMT) was held in Casablanca from April 19, 2018 to April 21, 2018, with the aim of fostering hematopoietic stem cell transplantation (HSCT) activity in Africa. Out of the 54 African countries, HSCT is available only in six (Algeria, Egypt, Morocco, Nigeria, South Africa, and Tunisia). During this meeting, African teams and international experts from the Worldwide Network for Blood and Marrow Transplantation (WBMT) gathered to share...
Source: Hematology Oncology and Stem Cell Therapy - June 4, 2019 Category: Cancer & Oncology Source Type: research

Epidemiological, Clinical, and Severity Characterization of Sickle Cell Disease in a Population from the Brazilian Amazon
ConclusionOur results represent the first comprehensive characterization of epidemiological, laboratorial, and clinical data of SCD in the region of the Brazilian Amazon. Despite the higher contribution of Amerindian ancestry previously demonstrated in this region, the main clinical characteristics of SCD seem similar to those reported in other populations. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - May 29, 2019 Category: Cancer & Oncology Source Type: research

Updates in Prognostication and Treatment of Waldenström’s Macroglobulinemia
Publication date: Available online 28 May 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Pooja Advani, Aneel Paulus, Sikander AilawadhiAbstractWaldenström’s macroglobulinemia (WM) is a rare, incurable hematologic disorder with a relatively indolent course in a majority of the patients. Despite this, a significant proportion of patients require treatment because of hypersecretion of immunoglobulin M and the invasion of bone marrow and peripheral organs by neoplastic lymphoplasmacytic lymphoma cells. Historically, there has been a dearth of research and therapeutic advancements in the field of WM, with mo...
Source: Hematology Oncology and Stem Cell Therapy - May 29, 2019 Category: Cancer & Oncology Source Type: research

Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia With an e14a3 BCR-ABL1 Fusion: The Role of Molecular Monitoring
Publication date: Available online 28 May 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Mireille Crampe, Stephen E. Langabeer, David O'Brien, Eileen Ryan, C. Larry Bacon (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - May 29, 2019 Category: Cancer & Oncology Source Type: research

Updates in Prognostication and Treatment of Waldenström’s Macroglobulinemia
Publication date: Available online 29 May 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Pooja Advani, Aneel Paulus, Sikander AilawadhiAbstractWaldenström’s macroglobulinemia (WM) is a rare, incurable hematologic disorder with a relatively indolent course in a majority of the patients. Despite this, a significant proportion of patients require treatment because of hypersecretion of immunoglobulin M and the invasion of bone marrow and peripheral organs by neoplastic lymphoplasmacytic lymphoma cells. Historically, there has been a dearth of research and therapeutic advancements in the field of WM, with mo...
Source: Hematology Oncology and Stem Cell Therapy - May 29, 2019 Category: Cancer & Oncology Source Type: research

Isoderivative chromosome 17 with multiple copies of RARα–PML fusions and Tp53 deletion in a rare case of APML
We report a case of adult APML with amplification of RARα/PML fusion protein, a consequence of isoderivative 17 with duplication of normal chromosome 15 and 17 and Tp53 deletion on derivative 17. Immunophenotyping by flow cytometry, presence of pancytopenia and epistaxis helped classify the patient as APML. FISH was used for confirmation of the same and indicated involvement of additional abnormalities. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - April 21, 2019 Category: Cancer & Oncology Source Type: research

Isoderivative Chromosome 17 With Multiple Copies of RARA–PML Fusions and Tp53 Deletion in a Rare Case of APML
Publication date: Available online 6 April 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Dhanlaxmi Shetty, Elizabeth Talker, Manju Sengar, P.G. Subramanian (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - April 7, 2019 Category: Cancer & Oncology Source Type: research

Intraocular Involvement of Mantle Cell Lymphoma: A Case report and Literature review
Publication date: Available online 6 April 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Madiha Iqbal, Yennifer Gil Castano, Taimur Sher, Mohamed A. Kharfan-DabajaAbstractLymphomatous involvement of the ocular adnexal region (OAR) is generally rare; however, it constitutes the most common ocular malignancy. Most cases of ocular adnexal lymphomas are extra nodal marginal zone B cell lymphomas. Mantle cell lymphoma involvement (MCL) of the OAR is a less common presentation compared with other lymphomas and it has been reported anecdotally. Studies have suggested an association of OAR involvement with poor p...
Source: Hematology Oncology and Stem Cell Therapy - April 7, 2019 Category: Cancer & Oncology Source Type: research

Splenectomy Following JAK1/JAK2 Inhibitor Therapy in Patients With Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation
ConclusionSplenectomy before alloHSCT might be a promising option in patients who failed to achieve significant spleen response after ruxolitinib therapy. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - April 7, 2019 Category: Cancer & Oncology Source Type: research

Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years
We report our institutional experience with HSCT in patients aged ≥70 years. A cohort of 22 patients underwent HSCT. Median overall survival was 5.16 years [95% confidence interval (CI): 1.5–8.7 years], and median post-transplant survival was 2.2 years (myelodysplastic syndrome: median 1.3 years, 95% CI: 4.7 months–2.2 years; acute myeloid leukemia: median not reached). Thirty-day mortality following transplantation was 9.5% (n = 2). These data provide further support for the use of transplantation in selected older patients, and highlight the impact of HSCT on overall survival among a patient cohor...
Source: Hematology Oncology and Stem Cell Therapy - March 4, 2019 Category: Cancer & Oncology Source Type: research

The Prevalence and Prognostic Significance of Autoimmune Cytopenias in a Cohort of Egyptian Patients With Chronic Lymphocytic Leukemia
ConclusionWe have shown a prevalence of 11.8% for AIC among our CLL patients. AIC was associated with unsatisfactory normalization of the hematological parameters even with therapy and lower number of patients with CLL downstaging in comparison with patients without AIC. These results suggest that AIC is a fingerprint of a biologically more aggressive disease even if no significant impact on overall survival was found. (Source: Hematology Oncology and Stem Cell Therapy)
Source: Hematology Oncology and Stem Cell Therapy - February 21, 2019 Category: Cancer & Oncology Source Type: research